Agios gets 90-day positive catalyst watch at Citi
TL;DR
Citi initiates Agios Pharmaceuticals with a Buy rating and a 90-day positive catalyst watch, driven by progress in drug development, including Pyrukynd's potential in thalassemia and sickle cell disease, and recent regulatory approvals. The firm raises its fair value estimate to $36.00, citing higher revenue growth and profitability expectations, while noting risks like regulatory uncertainties and share volatility. Investors should watch upcoming FDA decisions and clinical updates for further valuation impact.
Tags
Agios gets 90-day positive catalyst watch at Citi
Citi has initiated Agios Pharmaceuticals with a Buy rating and established a 90-day positive catalyst watch, citing progress in its drug development pipeline and regulatory milestones. The firm's analysis highlights Pyrukynd (mitapivat) as a key growth driver, particularly in thalassemia, where Phase 3 data supports potential approval, and in sickle cell disease (SCD), despite mixed results from the RISE UP trial according to Citi's analysis. Citi also notes the U.S. FDA's recent approval of AQVESME (mitapivat) for thalassemia-related anemia and a positive opinion from the EMA for Pyrukynd's expanded thalassemia indication, reinforcing near-term catalysts.
The analyst-updated fair value estimate for Agios rose to $36.00 from $32.13, reflecting higher revenue growth assumptions (115.05% vs. 111.60%) and improved profitability expectations. Citi's optimism aligns with broader bullish sentiment, as firms like BofA and H.C. Wainwright also maintain Buy ratings, emphasizing regulatory clarity and M&A tailwinds in the biopharma sector. However, risks persist, including regulatory uncertainties around mitapivat's SCD approval and historical share price volatility.
While Citi's positive outlook contrasts with more cautious ratings from JPMorgan and RBC, which cite limited patient-focused endpoints in SCD trials, the firm underscores Agios' near-term data reads and capital access as critical factors. Investors are advised to monitor upcoming FDA decisions and clinical updates, which could further shape valuation dynamics.
